| Michael D Kelley, PA | |
|
3535 Southern Blvd, Kettering, OH 45429-1221 | |
| (937) 395-6665 | |
| (937) 395-6668 |
| Full Name | Michael D Kelley |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 20 Years |
| Location | 3535 Southern Blvd, Kettering, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043284698 | NPI | - | NPPES |
| 0085230 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AS0400X | Physician Assistant - Surgical | 50003217 (Ohio) | Secondary |
| 363A00000X | Physician Assistant | 50003217 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kettering Medical Center | Kettering, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kettering Independent Medical Group Inc | 3173710936 | 586 |
| Ryan Hinman Md Llc | 0941594907 | 4 |
News Archive
The survival rate of cancer patients can drop to ten percent or less during metastasis, the spread of cancerous cells to create secondary tumors.
In just a few short months, hospitals across the country will start their annual push to make sure their workers get vaccinated against influenza, to protect themselves and others. Memories of the last flu season – one of the worst in years – still linger.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.
New findings are now being presented on possible mechanisms behind gender differences in the occurrence of rheumatism and other autoimmune diseases. The study, published in Nature Communications, can be of significance for the future treatment of diseases.
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael D Kelley, PA 3535 Southern Blvd, Kettering, OH 45429-1221 Ph: (937) 395-6665 | Michael D Kelley, PA 3535 Southern Blvd, Kettering, OH 45429-1221 Ph: (937) 395-6665 |
News Archive
The survival rate of cancer patients can drop to ten percent or less during metastasis, the spread of cancerous cells to create secondary tumors.
In just a few short months, hospitals across the country will start their annual push to make sure their workers get vaccinated against influenza, to protect themselves and others. Memories of the last flu season – one of the worst in years – still linger.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.
New findings are now being presented on possible mechanisms behind gender differences in the occurrence of rheumatism and other autoimmune diseases. The study, published in Nature Communications, can be of significance for the future treatment of diseases.
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
› Verified 1 days ago
Milena Menchaca, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 3535 Southern Blvd, Kettering, OH 45429 Phone: 937-395-8166 | |
Annabeth Pruett Barry, PA-C, MBA Physician Assistant Medicare: Medicare Enrolled Practice Location: 424 E Stroop Rd Unit B, Kettering, OH 45429 Phone: 937-562-2300 Fax: 937-562-2302 | |
Miss Kathryn Paige Combs, MPAS, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3535 Southern Blvd, Kettering, OH 45429 Phone: 937-395-8166 | |
Marie Therese Mualla Oram, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3700 Southern Blvd Ste 300, Kettering, OH 45429 Phone: 937-643-9299 Fax: 937-643-2343 | |
Lydia Nicole Little, PA-C Physician Assistant Medicare: May Accept Medicare Assignments Practice Location: 3535 Southern Blvd, Kettering, OH 45429 Phone: 937-643-9299 Fax: 937-643-2343 | |
Mr. David Evans, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3533 Southern Blvd Ste 2250, Kettering, OH 45429 Phone: 937-534-0330 Fax: 937-522-8995 |